Introduction
Prader Willi syndrome is a genetic disorder associated with learning disability, hyperphagia and obesity which leads to early development of obesity related complications. The weight and appetite management remains a challenge with not much success with appetite suppressant drugs and bariatric surgery. GLP-1 receptor analogues appear to be a promising alternative given their effect on appetite control, weight loss and HbA1c and were shown to decrease the levels of plasma ghrelin in PWS patients.
Conclusions
Although there are only few cases reported on GLP1-RA use in PWS patients the results are encouraging given the potential possibility of extending the use of these agents for obesity management in future. 
